Filter your results
- 3
- 1
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective studyRheumatology, 2021, pp.keab116. ⟨10.1093/rheumatology/keab116⟩
Journal articles
pasteur-03236464v1
|
||
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort studyRheumatology, 2022, in press, ⟨10.1093/rheumatology/keac107⟩
Journal articles
pasteur-03610530v1
|
|||
Early systemic inflammation induces neurodevelopmental disorders: results from ARTEMIS, a French multicenter study of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders and meta-analysisMolecular Psychiatry, 2023, ⟨10.1038/s41380-023-01980-w⟩
Journal articles
hal-03985785v1
|
|||
|
A child with severe juvenile dermatomyositis treated with ruxolitinibBrain - A Journal of Neurology , 2018, 141 (11), pp.e80. ⟨10.1093/brain/awy255⟩
Journal articles
pasteur-01963025v1
|